Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma

Fig. 2

Synergistic effects of enzastaurin and ibrutinib on the induction of cell death in DLBCL cells. a Cell viability of HBL-1, TMD8, SU-DHL-2, OCI-LY7 and SU-DHL-6 incubated with varying concentrations of ibrutinib, in the presence or absence of fixed minimally toxic concentrations of enzastaurin for 72 h. Cell Titer-Glo luminescent assay were performed to detect the inhibition rate. b Combination index form for each combination of enzastaurin and ibrutinib was calculated by CalcuSyn software. CI values less than 1.0 denote a synergistic interaction. c Cells were treated with indicated concentration of enzastaurin and ibrutinib for different time intervals (24 h, 48 h, 72 h), cell viability was monitored by Cell Titer-Glo luminescent assay. Inhibition rates = (1-dosing/control) × 100%. Error bars represent mean ± SD of triplicates. ENZ, enzastaurin; IBR, ibrutinib; Combo, enzastaurin combined with ibrutinib

Back to article page